Dentists in Orosi, CA Accepting Medicare
5 Dentists found. Showing 1 - 5
 Dr. Nonato H Elazegui, DMD Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 12384 Avenue 416 Ste Ab, Orosi, CA 93647 Phone: 559-528-2244 Fax: 559-528-4460 |
Dr. Isaac R. Navarro, DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 12586 Ave. 408, Orosi, CA 93647 Phone: 559-528-2804 Fax: 559-528-7623 |
 Rupinder Kaur Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 12586 Avenue 408, Orosi, CA 93647 Phone: 877-960-3426 |
Dr. Mitchell Arthur Thompson, DDS Dentist Medicare: Medicare Enrolled Practice Location: 12586 Avenue 408, Orosi, CA 93647 Phone: 877-960-3426 |
Dr. Alma Sanchez, DDS Dentist Medicare: Medicare Enrolled Practice Location: 12586 Ave. 408, Orosi, CA 93647 Phone: 559-528-2804 Fax: 559-528-7623 |
News Archive
FDA accepts Eisai's sNDA for perampanel drug for treatment of PGTC seizures
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted for review the company's Supplemental New Drug Application (sNDA) for its in-house-discovered AMPA receptor antagonist perampanel for the treatment of primary generalized tonic-clonic (PGTC) seizures.
Ischaemic heart disease patients at risk after 1 week of treatment
New study data presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate a high prevalence of NSAID prescriptions in patients at risk of ischaemic heart disease.
Human evolution in genetic fast lane
Countering a common theory that human evolution has slowed to a crawl or even stopped in modern humans, a new study examining data from an international genomics project describes the past 40,000 years as a time of supercharged evolutionary change, driven by exponential population growth and cultural shifts.
Innate Therapeutics receives funding to conduct Phase 2A clinical trial for MIS416
Innate Therapeutics today announced funding support from Fast Forward, LLC, a not-for-profit organization established by the U.S. National Multiple Sclerosis Society and EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany. The award of funds will help support the conduct of a Phase 2A clinical trial in patients with progressive forms of MS using MIS416, a naturally occurring agent derived from bacteria.
› Verified 6 days ago